GT
APGE

Glenmede Trust’s Apogee Therapeutics APGE Stock Holding History

Glenmede Trust’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$812K Sell
6,120
-4,679
-43% -$422K ﹤0.01% 839
2026
Q1 		$909K Buy
10,799
+2,287
+27% +$166K ﹤0.01% 767
2025
Q4 		$642K Buy
+8,512
New +$536K ﹤0.01% 865
2025
Q1 		$221K Sell
5,915
-8
-0.1% -$309 ﹤0.01% 1183
2024
Q4 		$268K Hold
5,923
– – ﹤0.01% 1140
2024
Q3 		$348K Sell
5,923
-137
-2% -$6.56K ﹤0.01% 1050
2024
Q2 		$238K Buy
6,060
+178
+3% +$8.64K ﹤0.01% 1128
2024
Q1 		$391K Buy
+5,882
New +$257K ﹤0.01% 988

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Glenmede Trust's APGE Position: Q2 2026 in Review

Glenmede Trust reduced its Apogee Therapeutics (APGE) stake by 43% in Q2 2026, selling an estimated $422K and leaving 6,120 shares worth $812K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Glenmede Trust first reported a position in APGE in Q1 2024 and has held it in 8 quarters since. The position peaked at $909K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Glenmede Trust held 6,120 shares of Apogee Therapeutics worth $812K as of Q2 2026.
  • Glenmede Trust sold 4,679 Apogee Therapeutics shares in Q2 2026, an estimated $422K.
  • Apogee Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #839 holding.
  • Glenmede Trust first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Glenmede Trust's Apogee Therapeutics position peaked at $909K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.